Hajikarimloo Bardia, Tos Salem M, Mohammadzadeh Ibrahim, Habibi Mohammad Amin
Department of Neurological Surgery, University of Virginia, Charlottesville, VA, USA.
Skull Base Research Center, Loghman-Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Pituitary. 2025 Aug 30;28(5):94. doi: 10.1007/s11102-025-01568-3.
Nelson's syndrome (NS) is an uncommon but serious complication after bilateral adrenalectomy (BA) in patients with Cushing's disease (CD). Stereotactic radiosurgery (SRS) has increasingly been used as a treatment option for NS patients; however, its effectiveness and safety remain uncertain. This meta-analysis aims to assess the role of SRS in NS.
A systematic review and meta-analysis were conducted following PRISMA guidelines. PubMed, Embase, Scopus, and Web of Science were searched through June 11, 2025, for studies reporting outcomes of SRS in NS. Pooled estimates were calculated for local control (LC), endocrine remission (ER), new pituitary dysfunction (NPD), salvage treatment (ST), and adverse radiation effects (ARE).
Seven studies with 122 patients were included. Pooled LC was 95% (95% CI: 89-99%), ER was 21% (95% CI: 13-30%), NPD was 20% (95% CI: 11-31%), ST was 4% (95% CI: 0-9%), and ARE was 0% (95% CI: 0-11%). Meta-regression analysis revealed that larger lesion volume, longer interval from prior resection, and higher pre-SRS ACTH levels were significantly associated with an increased risk of ARE.
SRS provides high local control rates and a low safety risk for NS patients, although endocrine remission remains limited. These results support SRS as a viable choice in multidisciplinary management, although further prospective studies are needed.
尼尔森综合征(NS)是库欣病(CD)患者双侧肾上腺切除术后一种罕见但严重的并发症。立体定向放射外科(SRS)越来越多地被用作NS患者的一种治疗选择;然而,其有效性和安全性仍不确定。本荟萃分析旨在评估SRS在NS中的作用。
按照PRISMA指南进行系统评价和荟萃分析。检索了截至2025年6月11日的PubMed、Embase、Scopus和Web of Science,以查找报告SRS治疗NS结果的研究。计算局部控制(LC)、内分泌缓解(ER)、新的垂体功能障碍(NPD)、挽救治疗(ST)和放射性不良反应(ARE)的合并估计值。
纳入了7项研究,共122例患者。合并的LC为95%(95%CI:89-99%),ER为21%(95%CI:13-30%),NPD为20%(95%CI:11-31%),ST为4%(95%CI:0-9%),ARE为0%(95%CI:0-11%)。Meta回归分析显示,更大的病变体积、距先前切除的间隔时间更长以及SRS前更高的促肾上腺皮质激素(ACTH)水平与ARE风险增加显著相关。
SRS为NS患者提供了较高的局部控制率和较低的安全风险,尽管内分泌缓解仍然有限。这些结果支持SRS作为多学科管理中的一种可行选择,尽管还需要进一步的前瞻性研究。